The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II multi-institutional trial of anlotinib plus docetaxel versus docetaxel in EGFR-wild-type non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy: ALTER-L018.
 
Lin Wu
No Relationships to Disclose
 
Zhijun Wu
No Relationships to Disclose
 
Zemin Xiao
No Relationships to Disclose
 
Jie Weng
No Relationships to Disclose
 
Zhongsha Ma
No Relationships to Disclose
 
Yanhua Chen
No Relationships to Disclose
 
Maoliang Xiao
No Relationships to Disclose
 
Yongqing Cao
No Relationships to Disclose
 
Huaxin Duan
No Relationships to Disclose
 
Peiguo Cao
No Relationships to Disclose
 
Hui Zhang
No Relationships to Disclose
 
Qianzhi Wang
No Relationships to Disclose
 
Jia Li
No Relationships to Disclose
 
Yan Xu
No Relationships to Disclose
 
Xingxiang Pu
No Relationships to Disclose
 
Kang Li
No Relationships to Disclose